Welcome to our dedicated page for Corbus Pharmaceuticals Holdings SEC filings (Ticker: CRBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Corbus Pharmaceuticals Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Corbus Pharmaceuticals Holdings's regulatory disclosures and financial reporting.
Corbus Pharmaceuticals Holdings, Inc. filed a Form 3 indicating that Chief Business Officer Nishant C. Saxena directly holds 3,500 shares of Common Stock, par value $0.0001 per share. This filing establishes his reported equity position as an officer of the company.
Corbus Pharmaceuticals director Winston Kung received new equity awards as part of his compensation. On May 19, 2026, he was granted 3,800 restricted stock units (RSUs), which will settle in common shares and vest 100% one year from the grant date. Following this award, his direct common stock holdings total 14,166 shares, including 8,600 unvested RSUs subject to their existing vesting schedules. On the same date, he also received stock options for 12,300 shares of common stock at an exercise price of $9.15 per share, which will also vest in full on the one-year anniversary of the grant.
Corbus Pharmaceuticals Holdings director Rachelle Suzanne Jacques received new equity awards. On May 19, 2026, she was granted 3,800 restricted stock units that will be settled in common shares and vest 100% one year after the grant date. The filing notes her common stock holdings total 11,383 shares, including 8,600 unvested RSUs subject to prior vesting schedules. She was also granted options to purchase 12,300 shares of common stock at an exercise price of $9.15 per share, which will vest 100% on the one-year anniversary of the grant, under the company’s 2024 Equity Compensation Plan.
Corbus Pharmaceuticals Holdings director John Kenneth Jenkins received new equity compensation. On May 19, 2026, he was granted 3,800 restricted stock units that will settle in common shares and vest 100% one year after the grant date. He was also granted stock options on 12,300 shares of common stock at an exercise price of $9.15 per share, which likewise vest fully on the one-year anniversary of grant under the company’s 2024 Equity Compensation Plan. Following these awards, his reported beneficial ownership is 8,633 shares of common stock, including 8,600 unvested RSUs subject to their vesting schedules.
Corbus Pharmaceuticals Holdings, Inc. director Anne Altmeyer reported equity compensation awards. On May 19, 2026, she received 3,800 restricted stock units (RSUs) that will vest 100% one year from the grant date and be settled in common shares. She was also granted stock options on 12,300 shares of common stock at an exercise price of $9.15 per share, which will likewise vest 100% after one year. Following the RSU grant, she directly holds 9,991 shares of common stock, and the disclosure notes this amount includes 8,600 unvested RSUs subject to prior vesting schedules.
Corbus Pharmaceuticals director Ben Yong received new equity awards as part of his compensation. On May 19, he was granted 3,800 restricted stock units that will convert into common shares after they vest in full one year from the grant date.
He also received stock options for 12,300 shares of common stock at an exercise price of $9.15 per share, which will also vest 100% after one year under the company’s 2024 Equity Compensation Plan. Following these awards, he directly holds 11,383 shares of common stock, including previously reported unvested RSUs.
Corbus Pharmaceuticals director Brent Pfeiffenberger received new equity awards as part of his compensation. On May 19, 2026, he was granted 7,500 restricted stock units that will settle in common shares and vest in three equal annual installments over three years, subject to continued service. He also received options on 24,700 shares of common stock at an exercise price of $9.15 per share, expiring on May 19, 2036, which will vest on the same three-year schedule under the company’s 2024 Equity Compensation Plan. Following these awards, his reported holdings include 7,500 shares of common stock and 24,700 stock options, all held directly.
Corbus Pharmaceuticals Holdings, Inc. director Brent Pfeiffenberger filed an initial ownership report on Form 3. The filing lists him as a director of the company but does not report any share transactions or holdings in this snapshot, serving as a baseline disclosure of his insider status.
Corbus Pharmaceuticals Holdings, Inc. has entered a two‑year employment agreement with Nishant Saxena, appointing him as Chief Business Officer effective May 21, 2026. His package includes a $470,000 base salary, a target bonus up to 40% of salary, and sizable stock‑based incentives.
Saxena will receive 192,300 stock options and 58,300 restricted stock units, with multi‑year vesting and enhanced severance and equity acceleration if he is terminated without cause or leaves for good reason, particularly around a change in control. The company also granted director Brent Pfeiffenberger 24,700 options and 7,500 RSUs under its 2024 Equity Incentive Plan.
Corbus announced a May 26, 2026 conference call and webcast to discuss updated Phase 1/2 data for its Nectin‑4 antibody‑drug conjugate CRB‑701 in head and neck squamous cell carcinoma and cervical cancer, ahead of presentations at the 2026 ASCO Annual Meeting.
Corbus Pharmaceuticals Holdings, Inc. Schedule 13G/A Amendment No. 2 reports that Octagon Capital Advisors LP, Octagon Investments Master Fund LP and Ting Jia jointly report 0 shares beneficially owned, representing 0.0% of Common Stock based on 17,736,464 Common Shares outstanding as of March 23, 2026. The filing states Octagon is the Master Fund's investment manager and Dr. Jia is Octagon's managing member; the Master Fund holds any Common Shares for the benefit of its investors. Signatures are dated May 14, 2026.